Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025
TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Subscribe To Our Newsletter & Stay Updated
